BACKGROUND: A reliable challenge model is needed to evaluate Helicobacter pylori vaccine candidates. METHODS: A cag pathogenicity island negative, OipA positive, multiple antibiotic susceptible strain of H pylori obtained from an individual with mild gastritis (Baylor strain 100) was used to challenge volunteers. Volunteers received 40 mg of famotidine at bedtime and 10(4)-10(10) cfu of H pylori in beef broth the next morning. Infection was confirmed by (13)C urea breath test ((13)C-UBT), culture, and histology. Eradication therapy was given four or 12 weeks post challenge and eradication was confirmed by at least two separate UBTs, as well as culture and histology. RESULTS: Twenty subjects (nine women and 11 men; aged 23-33 years) received a H pylori challenge. Eighteen (90%) became infected. Mild to moderate dyspeptic symptoms occurred, peaked between days 9 and 12, and resolved. Vomitus from one subject contained >10(3) viable/ml H pylori. By two weeks post challenge gastric histology showed typical chronic H pylori gastritis with intense acute and chronic inflammation. The density of H pylori (as assessed by cfu/biopsy) was similarly independent of the challenge dose. A minimal infectious dose was not found. Gastric mucosal interleukin 8 levels increased more than 20-fold by two weeks after the challenge. CONCLUSION: Challenge reliably resulted in H pylori infection. Infection was associated with typical H pylori gastritis with intense polymorphonuclear cell infiltration and interleukin 8 induction in gastric mucosa, despite absence of the cag pathogenicity island. Experimental H pylori infection is one of the viable approaches to evaluate vaccine candidates.
BACKGROUND: A reliable challenge model is needed to evaluate Helicobacter pylori vaccine candidates. METHODS: A cag pathogenicity island negative, OipA positive, multiple antibiotic susceptible strain of H pylori obtained from an individual with mild gastritis (Baylor strain 100) was used to challenge volunteers. Volunteers received 40 mg of famotidine at bedtime and 10(4)-10(10) cfu of H pylori in beef broth the next morning. Infection was confirmed by (13)C urea breath test ((13)C-UBT), culture, and histology. Eradication therapy was given four or 12 weeks post challenge and eradication was confirmed by at least two separate UBTs, as well as culture and histology. RESULTS: Twenty subjects (nine women and 11 men; aged 23-33 years) received a H pylori challenge. Eighteen (90%) became infected. Mild to moderate dyspeptic symptoms occurred, peaked between days 9 and 12, and resolved. Vomitus from one subject contained >10(3) viable/ml H pylori. By two weeks post challenge gastric histology showed typical chronic H pylori gastritis with intense acute and chronic inflammation. The density of H pylori (as assessed by cfu/biopsy) was similarly independent of the challenge dose. A minimal infectious dose was not found. Gastric mucosal interleukin 8 levels increased more than 20-fold by two weeks after the challenge. CONCLUSION: Challenge reliably resulted in H pylori infection. Infection was associated with typical H pylori gastritis with intense polymorphonuclear cell infiltration and interleukin 8 induction in gastric mucosa, despite absence of the cag pathogenicity island. Experimental H pylori infection is one of the viable approaches to evaluate vaccine candidates.
Authors: A K Mukhopadhyay; D Kersulyte; J Y Jeong; S Datta; Y Ito; A Chowdhury; S Chowdhury; A Santra; S K Bhattacharya; T Azuma; G B Nair; D E Berg Journal: J Bacteriol Date: 2000-06 Impact factor: 3.490
Authors: M Gerhard; N Lehn; N Neumayer; T Borén; R Rad; W Schepp; S Miehlke; M Classen; C Prinz Journal: Proc Natl Acad Sci U S A Date: 1999-10-26 Impact factor: 11.205
Authors: B Satin; G Del Giudice; V Della Bianca; S Dusi; C Laudanna; F Tonello; D Kelleher; R Rappuoli; C Montecucco; F Rossi Journal: J Exp Med Date: 2000-05-01 Impact factor: 14.307
Authors: Lina Fassi Fehri; Manuel Koch; Elena Belogolova; Hany Khalil; Christian Bolz; Behnam Kalali; Hans J Mollenkopf; Macarena Beigier-Bompadre; Alexander Karlas; Thomas Schneider; Yuri Churin; Markus Gerhard; Thomas F Meyer Journal: PLoS One Date: 2010-03-02 Impact factor: 3.240
Authors: Victor M Cardenas; Kristina D Mena; Melchor Ortiz; Sitrulasi Karri; Easwaran Variyam; Casey Barton Behravesh; Karen F Snowden; Ana Flisser; John R Bristol; Lillian F Mayberry; Ynes R Ortega; Yoshihiro Fukuda; Armando Campos; David Y Graham Journal: Public Health Rep Date: 2010 May-Jun Impact factor: 2.792
Authors: Laura Neumann; Mattea Mueller; Verena Moos; Frank Heller; Thomas F Meyer; Christoph Loddenkemper; Christian Bojarski; Michael Fehlings; Thomas Doerner; Kristina Allers; Toni Aebischer; Ralf Ignatius; Thomas Schneider Journal: J Immunol Date: 2016-07-25 Impact factor: 5.422